GISAID — LLMpedia

GISAID
Unknown authorUnknown author · Public domain · source
Name	Global Initiative on Sharing All Influenza Data
Abbreviation	GISAID
Type	Public–private partnership
Founded	2008
Founder	Peter Bogner
Headquarters	Munich
Area served	Worldwide
Focus	Influenza, coronaviruses, pathogen genomic data

Contents

GISAID The Global Initiative on Sharing All Influenza Data is an international platform for rapid sharing of viral genome sequences and associated metadata that rose to prominence during the 2009 H1N1 pandemic and the 2020 coronavirus pandemic. It facilitates collaboration among public health agencies, research institutes, national laboratories, and pharmaceutical firms such as Centers for Disease Control and Prevention, World Health Organization, European Centre for Disease Prevention and Control, National Institutes of Health, and Wellcome Trust. The platform has been central to surveillance efforts linking genomic surveillance to vaccine strain selection processes employed by bodies like the World Health Assembly and advisory groups such as the Global Influenza Surveillance and Response System.

History

GISAID originated from initiatives launched after the 1997 H5N1 outbreaks, when researchers at institutions including Centers for Disease Control and Prevention and World Health Organization sought mechanisms to improve timely sharing of sequences. The formal launch in 2008 followed consultations involving stakeholders from Food and Agriculture Organization, European Commission, and national public health laboratories in United States, United Kingdom, China, Japan, and Australia. Early contributors included influenza research groups at Mount Sinai Health System, Johns Hopkins University, and Institut Pasteur, which influenced uptake. The platform's visibility expanded during the 2009 influenza A(H1N1) pandemic and later in 2013 with Middle East respiratory syndrome coronavirus reports from Kingdom of Saudi Arabia and institutions such as King Faisal Specialist Hospital. During the 2019–2021 SARS-CoV-2 pandemic, submissions surged from laboratories like CDC Atlanta laboratory, CDC China, Karolinska Institute, Pasteur Institute Dakar, and private firms such as Moderna and Pfizer.

GISAID's stated mission emphasizes rapid sharing of influenza and coronavirus sequence data while protecting the rights of data generators, including recognition and attribution for sequence contributors from institutions such as National Institute of Virology (India), China CDC, and Robert Koch Institute. Core principles mirror norms promoted by intergovernmental forums including the World Health Organization and funding organizations like Bill & Melinda Gates Foundation and Wellcome Trust. The platform promotes collaborative use by vaccine manufacturers including Sanofi and GlaxoSmithKline and research consortia from European Molecular Biology Laboratory and Broad Institute. It aims to balance openness with safeguards similar to those discussed at meetings of the World Health Assembly and regional bodies like the African Union.

GISAID operates an online database that stores sequence data, metadata, and analysis tools contributed by laboratories such as Karolinska Institutet, University of Oxford, Harvard University, University of Tokyo, Institut Pasteur, and national reference centers. Users register under terms that require acknowledgement of originating and submitting laboratories—often national institutes like China CDC or Public Health England—and agree to usage conditions shaped by negotiations involving stakeholders such as World Health Organization advisory groups and funders including Wellcome Trust. The database supports genomic epidemiology workflows used by research groups at Johns Hopkins University, Imperial College London, and University of Cambridge and underpins variant tracking employed by agencies such as European Centre for Disease Prevention and Control.

Governance has included a board with representation from academic institutions like Harvard T.H. Chan School of Public Health, public health agencies including World Health Organization liaison roles, and contributors from philanthropic organizations such as Bill & Melinda Gates Foundation and Wellcome Trust. Funding sources have combined philanthropic grants, public contracts, and contributions from biomedical companies such as Moderna and Pfizer. Oversight and policy formulation have intersected with legal and ethical discussions involving entities like World Health Assembly delegations, national ministries of health in Germany and United States Department of Health and Human Services, and advisory inputs from groups associated with European Commission.

The platform enabled rapid sharing of SARS-CoV-2 sequences used by researchers at University of Oxford, National Institutes of Health, Scripps Research, and vaccine developers such as Pfizer and Moderna to design diagnostics and vaccines. Its data informed variant classifications by panels convened by World Health Organization and surveillance guidance adopted by agencies such as European Centre for Disease Prevention and Control and national public health institutes including Robert Koch Institute and Japan National Institute of Infectious Diseases. GISAID archives have been used in studies published by teams at Broad Institute, Wellcome Sanger Institute, Harvard Medical School, and University of California, San Francisco, and underpin international collaborations like the COVID-19 Genomics UK Consortium.

The organization has faced scrutiny over governance transparency, access conditions, and dispute resolution between sequence contributors and users involving actors such as national public health laboratories and private pharmaceutical firms. Debates have referenced positions from institutions including World Health Organization, Wellcome Trust, and national oversight bodies in Germany and United States Department of Health and Human Services. Critics from academic consortia like Open Science Framework advocates and commentators at journals such as Nature (journal) and Science (journal) have questioned access restrictions and proprietary terms. Supporters, including researchers at Johns Hopkins University and public health agencies such as European Centre for Disease Prevention and Control, argue that attribution policies encouraged rapid contributions from institutions in China, Brazil, South Africa, and India that otherwise might have been withheld. Legal and policy discussions have involved stakeholders such as World Health Organization member states, philanthropic funders like Bill & Melinda Gates Foundation, and academic publishers including Elsevier and Oxford University Press.

Category:Biological databases